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Abstract 
 
The changes introduced with the new (2018) compared with 
the previous (2013) European Hypertension Guidelines are 
herein highlighted together with some notable differences from 
current (2017) American Guidelines. Rhythmos 2018;13(4):71-
74.   
 
Key Words: hypertension; guidelines; drug therapy; resistant 
hypertension 
 
Abbreviations: BP = blood pressure; CV = cardiovascular; 
CVD = cardiovascular disease; HTN = hypertension 
  
CHANGES IN RECOMMENDATIONS 
 
Several changes, highlighted below, have been 
effected with the new (2018) European Society of 
Cardiology / European Society of Hypertension (ESC / 
ESH) Hypertension (HTN) guidelines 1 compared with the 
previous (2013) ones.2  
 
Diagnosis  
 
Previous recommendation of using office blood 
pressure (BP) for screening and diagnosis of HTN has been 
modified, but has remained class I recommendation. The 
new recommendation is to base the diagnosis of HTN on:              
• Repeated office BP measurements; or • Out-of-office BP 
measurement with ambulatory BP monitoring (ABPM) 
and/or home BP monitoring (HBPM) if logistically and 
economically feasible. 
 
 
Treatment Thresholds  
High-normal BP (130–139/85–89 mmHg). Previous 
(class III) recommendation indicating no initiation of 
antihypertensive drug therapy for high-normal BP has 
changed to class IIb: Drug treatment may be considered 
when cardiovascular (CV) risk is very high due to 
established CV disease (CVD), especially coronary artery 
disease (CAD). N.B.: The 2017 American (ACC/AHA) 
HTN Guidelines had also decreased the BP cutoff for 
treatment to >130/80 mmHg, suggesting that elevated BP 
should be treated earlier with lifestyle changes and in some 
patients with medication – at 130/80 mm Hg rather than 
140/90 mmHg. 3  
 
Treatment of low-risk grade 1 HTN. 
Recommendation for treatment of low-risk grade 1 HTN 
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has changed from class IIa to class I: In patients with grade 
1 HTN at low–moderate risk and without evidence of end-
organ damage, BP-lowering drug treatment is 
recommended if the patient remains hypertensive after a 
period of lifestyle intervention. 
Older patients. For older patients the 
recommendation also changed from class IIb to class I: 
BP-lowering drug treatment and lifestyle intervention is 
recommended in fit older patients (>65 years but not >80 
years) when systolic BP (SBP) is in the grade 1 range 
(140–159 mmHg), provided that treatment is well 
tolerated. 
 
 
BP Treatment Targets (Class I) 
 
• It is recommended that the first objective of treatment 
should be to lower BP to <140/90 mmHg in all patients 
and, provided that the treatment is well tolerated, treated 
BP values should be targeted to <130/80 mmHg in most 
patients. 
• In patients <65 years it is recommended that SBP should 
be lowered to a BP range of 120–129 mmHg in most 
patients. 
 
BP treatment targets in older patients (65–80 
years). In older patients (>65 years), it is recommended 
that SBP should be targeted to a BP range of 130–139 
mmHg (class I). 
 
BP treatment targets in patients aged over 80 years. 
An SBP target range of 130–139 mmHg is recommended 
for people older than 80 years, if tolerated (class I). 
 
Diastolic BP (DBP) targets. A DBP target of <80 
mmHg should be considered for all hypertensive patients, 
independent of the level of risk and comorbidities (class 
IIa). 
  
Initiation of Drug Treatment 
  
It is recommended to initiate an antihypertensive 
treatment with a two-drug combination, preferably in a 
single pill combination (SPC) (now class I). The 
exceptions are frail older patients and those at low risk and 
with grade 1 HTN (particularly if SBP is <150 mmHg). 
 
 
Resistant HTN 
 
Recommended treatment of resistant HTN is the 
addition of low-dose spironolactone to existing treatment, 
or the addition of further diuretic therapy if intolerant to 
spironolactone, with either eplerenone, amiloride, higher-
dose thiazide/thiazide-like diuretic or a loop diuretic, or the 
addition of bisoprolol or doxazosin (class I)  
  
   
Device-Based Therapy for HTN 
 
In case of ineffectiveness of drug treatment, invasive 
procedures such as renal denervation and baroreceptor 
stimulation, have been downgraded from class IIb to class 
III:  
Ɣ Use of device-based therapies is not recommended for 
the routine treatment of HTN, unless in the context of 
clinical studies and randomized controlled trials (RCTs), 
until further evidence regarding their safety and efficacy 
becomes available (Grade III). 
  
NEW SECTIONS 
 
New sections and topics have been added: 
Ɣ:KHQ WR VXVSHFW DQG KRZ WR VFUHHQ IRU WKH FDXVHV RI
secondary HTN 
Ɣ0DQDJHPHQWRIHTN emergencies 
Ɣ8SGDWHGUHFRPPHQGDWLRQVRQWKHPDQDJHPHQWRIBP in 
acute stroke 
Ɣ8SGDWHGUHFRPPHQGDWLRQVRQWKHPDQDJHPHQWRIHTN 
in women and pregnancy 
Ɣ+71LQdifferent ethnic groups 
Ɣ7KHeffects of altitude on BP 
Ɣ+71DQGchronic obstructive pulmonary disease 
Ɣ+71DQGAF and other arrhythmias 
ƔOral anticoagulant use in HTN 
Ɣ+71DQGsexual dysfunction 
Ɣ+71DQGcancer therapies 
ƔPerioperative management of HTN 
ƔGlucose-lowering drugs and BP 
Ɣ8SGDWHGUHFRPPHQGDWLRQVRQCV risk assessment and 
management: (i) using the SCORE system to assess risk 
in patients without CVD; (ii) the importance of HTN-
mediated organ damage (HMOD) in modifying CV risk; 
and (iii) the use of statins and aspirin for CVD prevention 
 
 
NEW CONCEPTS 
 
New concepts have been introduced:  
 
BP measurement  :LGHU XVH RI RXW-of-office BP 
measurement with ambulatory BP monitoring (ABPM) 
and/or home BP monitoring (HBPM), especially HBPM, 
as an option to confirm the diagnosis of HTN, detect white-
coat and masked HTN, and monitor BP control. 
 
Less conservative treatment of BP in older and very 
old patients:  
 
• Lower BP thresholds and treatment targets for older 
patients, with emphasis on considerations of biological 
rather than chronological age (i.e. the importance of frailty, 
independence, and the tolerability of treatment). 
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• Recommendation that treatment should never be denied 
or withdrawn on the basis of age, provided that treatment 
is tolerated. 
 
A Single-Pill combination (SPC) treatment strategy 
to improve BP control: 
• Preferred use of two-drug combination therapy for the 
initial treatment of most people with HTN 
• A single-pill treatment strategy for HTN with the 
preferred use of SPC therapy for most patients 
• Simplified drug treatment algorithms with the preferred 
use of an angiotensin converting enzyme (ACE) inhibitor 
or angiotensin-receptor blocker (ARB), combined with a 
calcium channel blocker (CCB) and/or a thiazide/thiazide-
like diuretic, as the core treatment strategy for most 
patients, with beta-blockers used for specific indications 
  
New target ranges for BP in treated patients: 
• Target BP ranges for treated patients to better identify the 
recommended BP target and lower safety boundaries for 
treated BP, according to a patient’s age and specific 
comorbidities. 
 
Detecting poor adherence to drug therapy: 
• A strong emphasis on the importance of evaluating 
treatment adherence as a major cause of poor BP control. 
 
A key role for nurses and pharmacists in the longer-
term management of HTN: 
• The important role of nurses and pharmacists in the 
education, support, and follow-up of treated hypertensive 
patients is emphasized as part of the overall strategy to 
improve BP control. 
 
COMPARISON WITH THE AMERICAN 
GUIDELINES 
 
Some of the European recommendations1 differ from 
those of the Americans3 (https://www.tctmd.com/news/new-
european-hypertension-guidelines-not-harmony-us-guidance). 
Two of the major changes, according to ESC chairperson 
%U\DQ:LOOLDPV DUH DQ HPSKDVLV RQ XVLQJ DW OHDVW WZR
drugs to initiate treatment in the vast majority of patients 
and on using single-pill combinations to boost compliance, 
which will also improve BP control rates. The focus 
remains on 3 main categories of antihypertensive drugs for 
most patients: blockers of the renin-angiotensin system 
(ACE inhibitors/ARBs), CCBs, and diuretics. Algorithms 
are provided to help guide clinician choices. 
 
Treatment thresholds and targets:LWKUHJDUGV WR
the differences from the US guidelines, the Europeans 
have maintained traditional BP categories, with grade 1 
HTN starting at an office BP of >140/90 mm Hg, whereas 
the Americans lowered the threshold for stage 1 HTN to 
130/80 mm Hg. The US recommendation is to initiate drug 
treatment to lower BP in patients in the range of 130 to 139 
mmHg range who have established CVD or an estimated 
10-year risk of at least 10%. Most of the recommendations 
in the ESC/ESH guideline propose treatment starting at 
140/90 mm Hg, though there may be people in the “high, 
high-normal” range who might get treatment if they have 
very high risk. “But that’s got to be an individual decision 
and we don’t think the evidence is very strong in support 
RI LW´ :LOOLDPV KDV VWDWHG www.tctmd.com/news/new-
european-hypertension-guidelines-not-harmony-us-
guidance).  
There is also a transatlantic difference regarding 
treatment goals; the Europeans have not adopted the target 
suggested by the SPRINT trial data4 to lower BP to 
<130/80 mmHg as the Americans have, who recommend 
this aggressive target for all adults, even those with various 
comorbidities, who have confirmed HTN and known CVD 
or a high estimated risk. 
 
The Europeans recommend target ranges, advising a 
systolic target of 120-130 mm Hg, but not lower, for most 
adults < 65. For adults >65, regardless of comorbidities, 
the treatment target range is the same as the one in younger 
patients with chronic kidney disease: <140 mm Hg, but not 
<130 mm Hg. For the European guidelines, the first 
priority for all patients is to lower systolic BP to < 140 mm 
Hg. It may be reasonable to aim for lower in younger 
patients who may tolerate these lower levels.  
 
Diagnosis. The new ESC/ESH guideline introduce the 
strategy of out-of-office BP-monitoring as equivalent with 
repeated office-based measures for confirming a diagnosis 
of HTN, when screening has detected high BP.1 They 
suggest that either home or ambulatory monitoring can be 
useful and occasionally may be preferred to repeated office 
measurements, e.g. for ruling out white coat HTN. 
Life-style changes. The guidelines also continue to 
emphasize the importance of lifestyle changes of smoking 
cessation, reducing salt intake (to <5 g/d), moderating 
alcohol consumption, engaging with regular aerobic 
exercise, and controlling body weight. These measures 
may prevent or delay the onset of HTN and reduce CV risk; 
they may even suffice to delay or obviate the need for drug 
therapy in patients with high-normal BP (130-139/85-89 
mmHg) or grade 1 HTN (140-159/90-99 mmHg). They 
can also enhance the effects of BP lowering therapy, but 
they should not delay the initiation of drug therapy in high-
risk patients. 
 
Device-based therapies. Another notable addition to 
the guidelines is a class III recommendation against using 
device-based therapies, apparently based on the results of 
74 
 
 
the SYMPLICITY HTN-3 trial.5 :KHWKHU WKH QHZ
SPYRAL HTN-ON MED trial (NCT02439775) will 
revive the procedure remains to be seen; a preliminary 
analysis of the results of the first 80 of 467 patients 
enrolled into the study and randomly assigned to renal 
denervation (n=38) or sham control (n=42) indicated that 
renal denervation in the main renal arteries and branches 
significantly reduced BP compared with sham control with 
no major adverse events.6   
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